These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 33178200)

  • 1. Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals.
    Ortiz de Landazuri I; Egri N; Muñoz-Sánchez G; Ortiz-Maldonado V; Bolaño V; Guijarro C; Pascal M; Juan M
    Front Immunol; 2020; 11():573179. PubMed ID: 33178200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
    Hu Y; Tan Su Yin E; Yang Y; Wu H; Wei G; Su J; Cui Q; Jin A; Yang L; Fu S; Zhou J; Qiu L; Zhang X; Liang A; Jing H; Li Y; Blaise D; Mohty M; Nagler A; Huang H
    Curr Res Transl Med; 2020 Aug; 68(3):111-118. PubMed ID: 32620465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
    Gardner RA; Ceppi F; Rivers J; Annesley C; Summers C; Taraseviciute A; Gust J; Leger KJ; Tarlock K; Cooper TM; Finney OC; Brakke H; Li DH; Park JR; Jensen MC
    Blood; 2019 Dec; 134(24):2149-2158. PubMed ID: 31697826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
    Frigault MJ; Nikiforow S; Mansour MK; Hu ZH; Horowitz MM; Riches ML; Hematti P; Turtle CJ; Zhang MJ; Perales MA; Pasquini MC
    Blood; 2020 Jul; 136(1):137-139. PubMed ID: 32457999
    [No Abstract]   [Full Text] [Related]  

  • 5. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxicities of CD19 CAR-T cell immunotherapy.
    Hirayama AV; Turtle CJ
    Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
    Bachanova V; Bishop MR; Dahi P; Dholaria B; Grupp SA; Hayes-Lattin B; Janakiram M; Maziarz RT; McGuirk JP; Nastoupil LJ; Oluwole OO; Perales MA; Porter DL; Riedell PA;
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1239-1246. PubMed ID: 32298807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.
    Sesques P; Bachy E; Ferrant E; Safar V; Gossez M; Morfin-Sherpa F; Venet F; Ader F
    Cancer Cell; 2022 Mar; 40(3):236-237. PubMed ID: 35093212
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
    Hill JA; Seo SK
    Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
    Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
    Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity.
    Schmidts A; Wehrli M; Maus MV
    Annu Rev Med; 2021 Jan; 72():365-382. PubMed ID: 32776808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.
    Kekre N; Hay KA; Webb JR; Mallick R; Balasundaram M; Sigrist MK; Clement AM; Nielsen JS; Quizi J; Yung E; Brown SD; Dreolini L; Waller DD; Smazynski J; Gierc NS; Loveless BC; Clark K; Dyer T; Hogg R; McCormick L; Gignac M; Bell S; Chapman DM; Bond D; Yong S; Fung R; Lockyer HM; Hodgson V; Murphy C; Subramanian A; Wiebe E; Yoganathan P; Medynski L; Vaillan DC; Black A; McDiarmid S; Kennah M; Hamelin L; Song K; Narayanan S; Rodrigo JA; Dupont S; Hawrysh T; Presseau J; Thavorn K; Lalu MM; Fergusson DA; Bell JC; Atkins H; Nelson BH; Holt RA
    Front Immunol; 2022; 13():1074740. PubMed ID: 36601119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical care management of chimeric antigen receptor T-cell therapy recipients.
    Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
    CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.